This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.
Science Hub

Welcome to Novo Nordisk Science Hub

The information on this website is intended for healthcare professionals only and is provided solely for the purpose of scientific exchange. By accessing this website you accept this legal disclaimer and you expressly confirm your status as a healthcare professional.


This website is not country specific and may therefore contain information that is not applicable to your country. The website is not intended to provide medical advice and/or treatment guidance. Therefore, before prescribing any product, always refer to information approved by regulatory authorities in your country such as the prescribing information and/or the Summary of Product Characteristics. Novo Nordisk accepts no liability for the accuracy, completeness or use of information on this website, and disclaims any liability to update the information contained on this website.

Are you a healthcare professional?

Speaker - Mary Rinella
Mary E.
University of Chicago Pritzker, Chicago, US

Mary E. Rinella is a Professor of Medicine at the University of Chicago Pritzker School of Medicine and is the Director of the Metabolic and Fatty Liver Program. Currently her focus is in clinical research in the area of non-alcoholic fatty liver disease (NAFLD)/Nonalcoholic steatohepatitis (NASH) both before and after liver transplantation. Dr. Rinella is actively involved in the American Association for the Study of Liver Diseases (AASLD) where she recently served as Councilor-at-large on the Governing Board.  She was an author on the 2018 AASLD Practice Guidance for NAFLD and the chair of the 2023 AASLD NAFLD Practice Guidance.  She has held several national leadership roles in the field of NAFLD including Chair of the AASLD NAFLD Special Interest Group (SIG) and currently as Chair of the AASLD NASH Task Force. She is the former chair of the NASH task force and current chair of the new AASLD steatotic liver disease task force. As former chair of the NASH Task Force, she was charged with fostering research collaboration and advancing best practice through collaboration with other medical societies, federal agencies and patient advocacy organizations to improve outcomes in patients with NASH.